Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

February 20, 2022

Primary Completion Date

September 1, 2023

Study Completion Date

October 31, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

BBV152

Each participant will receive 2 doses of the investigational product intramuscular injection of either 6 μg of BBV15 vaccine or placebo.

Trial Locations (10)

31904

RECRUITING

IACT Health, Columbus

33016

RECRUITING

Palm Springs Community Health Center, Miami Lakes

33122

RECRUITING

Angels Clinical Institute, Miami

33135

RECRUITING

Suncoast Research Group LLC, Miami

68510

RECRUITING

Jay Meyer Meridian Research, Lincoln

75071

RECRUITING

Wellness Clinical Research, McKinney

75149

RECRUITING

PRX Research, Dallas

85282

RECRUITING

Voyage Medical, Tempe

237803

RECRUITING

Meridian Research 3235 Academy Ave, Portsmouth

332789

RECRUITING

Clinical Site Partners, Winter Park

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ocugen

INDUSTRY